The overall response rate | Download Table
Cell therapy doubles survival, response rates in advanced melanoma
Objective response rate assessment in oncology: Current situation and future expectations
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM
Comparing Outcomes in Patients with Recurrent or Refractory Ovarian Cancer Managed with 1 of 2 Versions of Pegylated Liposomal Doxorubicin at an Academic Medical Center
BRAFTOVI + cetuximab | Overall Response Rate | ORR | BEACON CRC
Efficacy endpoints in Oncology
ODOMZO® (sonidegib) | Efficacy Data
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax's SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting | Dynavax Technologies Corporation
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris | BioSpace
Response rates Overall response rate and depth of response according to... | Download Scientific Diagram
Durable Response Rate
Durable Response Rate
Efficacy | BALVERSA® (erdafitinib) HCP
RESONATE-2 - Overall Response Rate | IMBRUVICA® (ibrutinib) HCP
Forest plot of the comparison of overall response rate (ORR).
Overall Response Rates - WM | IMBRUVICA® (ibrutinib) HCP
Overall Response Rate | CALQUENCE® (acalabrutinib) 100 mg tablets | For HCPs
ORR (Objective Response Rate) and related statistics – Part 1
What Low Response Rates Mean for Telephone Surveys | Pew Research Center
Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates | JCO Clinical Cancer Informatics
Response Rates for Waldenström Macroglobulinemia Improve With Use of New First-Line, Better-Tolerated Treatments - U.S. Medicine
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial | Nature Medicine
